Elevations of AGE and vascular endothelial growth factor with decreased total antioxidant status in the vitreous fluid of diabetic patients with retinopathy
Open Access
- 1 June 2005
- journal article
- research article
- Published by BMJ in British Journal of Ophthalmology
- Vol. 89 (6) , 673-675
- https://doi.org/10.1136/bjo.2004.055053
Abstract
Background/aims: Advanced glycation end product (AGE) induces vascular endothelial growth factor (VEGF) expression in cell culture and animal models, being considered to be involved in development of diabetic retinopathy; oxidative stress also has a part in diabetic retinopathy. However, the interrelations between AGE, VEGF, and oxidative stress remain to be elucidated. In this study, vitreous AGE, VEGF, and total antioxidant levels in were determined in diabetic patients with retinopathy, and the relations among them investigated. Methods: ELISA (enzyme linked immunosorbent assay) was used to determine the vitreous levels of AGE and VEGF in 41 patients with diabetic retinopathy and 28 non-diabetic control subjects. Total antioxidant levels in vitreous of 20 diabetic patients and 18 controls were also analysed by ELISA. Results: The vitreous levels of AGE and VEGF were significantly higher in diabetic patients than in control subjects (pConclusion: This study suggests that AGE and decreased total antioxidant status may contribute to the pathogenesis of diabetic retinopathy via induction of VEGF.Keywords
This publication has 13 references indexed in Scilit:
- Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy.2003
- Angiogenesis induced by advanced glycation end products and its prevention by cerivastatinThe FASEB Journal, 2002
- Advanced Glycation End Products-Induced Apoptosis and Overexpression of Vascular Endothelial Growth Factor in Bovine Retinal PericytesBiochemical and Biophysical Research Communications, 2002
- Therapeutic potential of anti-oxidants and diabetic retinopathyExpert Opinion on Investigational Drugs, 2001
- Increased levels of platelet-derived growth factor in vitreous fluid of patients with proliferative diabetic retinopathyExperimental and Clinical Endocrinology & Diabetes, 2000
- The national diabetic retinopathy laser treatment audit III. Clinical outcomesEye, 1999
- Advanced glycation end products increase retinal vascular endothelial growth factor expression.Journal of Clinical Investigation, 1998
- An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia.Archives of Ophthalmology (1950), 1997
- Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal DisordersNew England Journal of Medicine, 1994
- Glycation and inactivation of human Cu-Zn-superoxide dismutase. Identification of the in vitro glycated sites.Journal of Biological Chemistry, 1987